Elevated ectodomain of type 23 collagen is a novel biomarker of the intestinal epithelium to monitor disease activity in ulcerative colitis and Crohn’s disease

T. Manon-Jensen¹*, S. Sun¹, M. Lindholm¹, V. Domislović², P. Giuffrida³, M. Brinar², G. Mazza⁴, M. Pinzani⁴, Ž. Krznarić², A. Di Sabatino³, A. Karsdal¹, J.H. Mortensen¹*

¹Biomarkers and Research, Nordic Bioscience, Herlev, Denmark. ²Department of Gastroenterology and Hepatology, Clinical Hospital Centre Zagreb. ³First Department of Internal Medicine, San Matteo Hospital Foundation, University of Pavia, Pavia, Italy. ⁴University College of London, Institute for Liver and Digestive Health. London, UK.

*Corresponding author: Joachim H. Mortensen, Nordic Bioscience A/S, Herlev Hovedgade 205-207 2730 Herlev, Denmark. Tel. +45 4452 5252, Fax: +45 4452 5251, email: jhm@nordicbio.com

Running title: Elevated ectodomain of type 23 collagen in IBD

KEYWORDS: Collagen, serological biomarker, epithelium, inflammatory bowel disease.
Abstract

Background. Impaired intestinal epithelial barrier is highly affected in inflammatory bowel disease. Transmembrane collagens connecting the epithelial cells to the extracellular matrix have an important role in epithelial cell homeostasis. Thus, we sought to determine whether the transmembrane collagen type 23 collagen could serve as a surrogate marker for disease activity in patients with Crohn’s disease and ulcerative colitis.

Methods. We developed an ELISA (PRO-C23) to detect the ectodomain of type 23 collagen in serum, followed by evaluation of its levels in both acute and chronic dextran sulfate sodium colitis model in rats and human inflammatory bowel disease cohorts. Serum from 44 Crohn’s disease and 29 ulcerative colitis patients with active and inactive disease was included.

Results. In the acute and chronic dextran sulfate sodium induced rat colitis model, the PRO-C23 serum levels were significantly increased after colitis and returned to normal levels after disease remission. Serum levels of PRO-C23 were elevated in Crohn’s disease (p<0.05) and ulcerative colitis (p<0.001) patients with active disease compared to healthy donors. PRO-C23 differentiated healthy donors from ulcerative colitis (AUC: 0.81, p=0.0009) and Crohn’s disease (AUC: 0.70, p=0.0124). PRO-C23 differentiated ulcerative colitis patients with active disease from those in remission (AUC: 0.75, p=0.0219) and Crohn’s disease patients with active disease from those in remission (AUC: 0.68, p=0.05).

Conclusion. PRO-C23 was elevated in rats with active colitis, and inflammatory bowel disease patients with active disease. Therefore, PRO-C23 may be used as a surrogate marker for monitoring disease activity in ulcerative colitis and Crohn’s disease.
Key Summary

1. Summarize the established knowledge on this subject
   a. The intestinal permeability in CD and UC is impaired, which results in the invasion of numerous bacteria, followed by immune cell infiltration to the gut
   b. Increased tissue remodeling and loss of epithelial integrity is related to flares in CD and UC.
   c. Type 23 collagen is a transmembrane collagen and is expressed by intestinal epithelial cells and is therefore a marker of epithelium integrity

2. What was the significant and/or new findings of this study?
   a. A novel type 23 collagen marker was developed (PRO-C23), quantifying the ectodomain of type 23 collagen in serum.
   b. Elevated serum levels of PRO-C23 was demonstrated to be associated with DSS colitis rats (acute and chronic) and CD and UC patients with active disease
   c. PRO-C23 may potentially be used as a non-invasive surrogate of disease activity in CD and UC patients and thus aid in diagnosing and monitoring patients.
Introduction

The epithelium is important to maintain the health of the gut. However, in both Crohn’s disease (CD) and ulcerative colitis (UC), the intestinal permeability is impaired, which results in the invasion of numerous bacteria, followed by immune cell infiltration to the gut [1–3] and trigger bowel symptoms in inflammatory bowel disease (IBD) patients [4]. Type 23 collagen, a member of type II transmembrane protein family expressed by epithelial cells, was first identified in 2003 by Jacqueline Banyard et al. in rat metastatic tumor cells [5]. Type 23 collagen consists of a short cytoplasmic domain, a membrane-spanning domain, and a long ectodomain [5]. The newly synthesized type 23 collagen can be transported to the cell surface as a transmembrane protein, or cleaved intracellularly by furin, triggering release of the ectodomain into the ECM [6] (Fig 1).

Many studies have shown that some of the junction proteins were significantly down-regulated in IBD inflamed intestinal tissue[7–10], and increased extracellular matrix (ECM) remodeling is highly affected in both UC and CD, including remodeling of the basement membrane which is also related to epithelial cells driven by increased protease activity[11–19][20,21]. On this background it was likely that type 23 collagen was also affected by the ECM remodeling in UC and CD.

Type 23 collagen was found to be related to cell adhesion and metastasis in vitro [22,23]. Knockout type 23 collagen in such cell lines resulted in altered expression of cell adhesion molecules and impaired cell adhesion[22,23], which indicated that type 23 collagen might be a regulator of cell adhesion.

Since type 23 collagen is expressed in the intestinal epithelium [15], we hypothesized that it may be cleaved from the cell surface during epithelial damage in IBD and could be used as a potential biomarker to monitor disease activity. Therefore, we developed an enzyme-linked immunosorbent assay (ELISA) to detect the ectodomain of type 23 collagen in serum, followed by an evaluation of its levels in both dextran sulfate sodium (DSS) colitis models in rats and human IBD cohorts.
**Materials and methods**

**Antibody development for PRO-C23**

We used the last 10 amino acids of the type 23 collagen α1 chain \( ^{531} \text{GLPVPGCWHK}^{540} \), Genscript, USA) as the immunogenic peptide to generate specific monoclonal antibodies. The sequence homology of the peptide was 100% between human and rats. 4-6-week-old Balb/C mice were immunized subcutaneously with 100μg of the immunogen (KLH-CGG-GLPVPGCWHK) emulsified with Stimmune adjuvant (Thermo Fisher, USA). Consecutive immunizations were performed at 2-week intervals. Mouse spleen cells were fused with SP2/0 myeloma cells to form hybridomas. The hybridomas were raised in 96-well plates and cultured in IMDM + 10%FBS medium in the CO2-incubator. Hybridoma cells specific to the selection peptide and without cross-reactivity to elongated peptide (GLPVPGCWHKA), truncated peptide (GLPVPGCWH) or to deselection peptides (GLPVQGCWNK, type XIII collagen, GLPMPGCWQK, type XXV collagen) (Genscript, USA) were selected and subcloned. In the end, the supernatant was purified using an IgG column (GE health, USA). Briefly, the IgG column was washed with 10 column volume of 20mM PBS. The supernatant was applied in 4°C with 1ml/min speed. After supernatant ran through the column, the column was washed with 10 column volume of 20mM PBS to remove unspecific binding proteins. Antibodies were eluted with 0.1M Glycine pH 2.7, and dialysis with PBS buffer was subsequently performed.

**PRO-C23 assay and technical evaluation**

ELISA-plates used for the assay development were Streptavidin-coated from Roche (cat.: 11940279). All ELISA plates were analyzed with the ELISA reader from Molecular Devices, SpectraMax M, (CA, USA). We labeled the selected monoclonal antibody with horseradish peroxidase (HRP) using the Lightning link HRP labeling kit according to the instructions of the manufacturer (Innovabioscience, Babraham, Cambridge, UK). A 96-well streptavidin plate was coated with biotin-GLPVPGCWHK (Genscript, USA) and incubated 30 minutes at 20°C. Twenty μL of...
standard peptide (standard A had the highest concentration, and was diluted 2-fold) or samples were added to appropriate wells, followed by 100 µL of HRP conjugated monoclonal antibody 10F6, and incubated 20 hours at 4°C. Finally, 100 µL tetramethylbenzidine (TMB) (Kem-En-Tec cat.438OH) was added, and the plate was incubated 15 minutes at 20°C in the dark. The above incubation steps included shaking at 300 rpm. After each incubation step, the plate was washed 5 times. The TMB reaction was stopped by adding 100 µL of stopping solution (1% H₂SO₄) and measured at 450 nm with 650 nm as the reference.

The lower limit of detection (LLOD) was determined from 21 zero samples (i.e. buffer) and calculated as the mean + 3x standard deviation (SD). Upper limit of detection (ULOD) was determined as the mean – 3xSD of 10 measurements of Standard A. The intra-assay and inter-assay variations were the mean variations of 10 quality control (QC) samples run 10 independent times in duplicate. Dilution recovery was determined in 4 serum samples and 4 plasma samples and was calculated as a percentage of recovery of diluted samples from the 100% sample. Correlation between the PRO-C23 levels in healthy subjects with matched samples from serum -and plasma (heparin, citrate and EDTA) was determined in 16 samples (Innovative Research, USA). No additional information for these samples was available.

**Western blotting with recombinant human type 23 collagen**

Recombinant human type 23 collagen (R&D system, 4165-CL) was diluted in sample buffer containing 80 mM dithiothreitol (DTT) and run on a 10% SDS-PAGE gel, and subsequently transferred onto a nitrocellulose membrane. The nitrocellulose membranes were then blocked for non-specific binding by incubation for 1 hour at room temperature in tris-buffered saline-Tween® 20 (TBS-T) buffer containing 5% skim milk powder. This was followed by incubation with 1 µg/ml 10F6 or commercial type 23 collagen antibody (R&D system, MAB4165) diluted in TBS-T milk for overnight. The recombinant type 23 collagen for both commercial Ab and 10F6 were prepared together. Half
volume of recombinant protein was loaded for commercial Ab incubation. The other half volume
was loaded for 10F6 incubation. The loading and transfer were done using the same gel, which
ensures the equal transfer time. The recombinant protein demonstrated a 95% purity, which made
it unnecessary to normalize total protein expression. Then the membranes were washed in TBS-T 3
times, followed by incubation in the secondary peroxidase-conjugated antibody. The secondary Ab
(Jackson, 315-035-045, 1:5000 dilution) was incubated at room temperature for 1 hour. Finally, the
membranes were washed in TBS-T 3 times, and the results were visualized using the enhanced
chemiluminescence (ECL) system (GE healthcare, cat# RPN2109).

DSS rat model

Male Sprague–Dawley rats, 12 weeks of age, were used for both the acute DSS colitis study and the
chronic DSS colitis model. The rats were divided into 2 groups: 6% DSS group (n = 12) and a water
control group (n = 9) for the acute DSS colitis model. Acute DSS colitis was induced by administration
of 6% DSS in the drinking water for 5 days, while control rats received regular drinking water. After
5 days of DSS administration, DSS was withdrawn, and regular drinking water was administered until
the end of the study at day 16. 6 DSS rats and 3 control rats were sacrificed on day 6. The rats were
fasted over-night before blood was drawn from the tail vein on day 0 (n = 21), 6 (n = 9), 7 (n = 12),
and 16 (n = 12). The rats were also divided into 2 groups: 5% DSS group (n = 36) and water control
group (n=12) for the chronic DSS colitis model. Chronic DSS colitis was induced by administrating 5%
DSS in the drinking water for 4 cycles for 7 days with 7 days recovery period with drinking water
without DSS. The rats were fasted over-night before blood was drawn from the tail vein on day 0 (n
= 48), 7 (n = 48), 14 (n = 42), 21 (n = 39), 28 (n =36 ), 35 (n = 33), 42 (n = 30), 49 (n = 27), 56 (n = 24).
The disease progression for both acute and chronic DSS colitis models was evaluated using the
Disease Activity Index (DAI), which was scored each day of the study and has been described
previously [14]. The DSS in vivo study’s ethical guidelines were followed in accordance with the


legislation and under ethical approval of the “Dyreforsøgstilsynet” (agreement number: 2017-15-0201-01171).

**IBD cohorts**

3 different cohorts were measured to evaluate the biological relevance of the PRO-C23 assay. Cohort 1 was used in assay development to evaluate the biological relevance of PRO-C23 in IBD, while cohort 2 and 3 were included to validate the findings in cohort 1 and further assess the applicability of PRO-C23 regarding disease activity in IBD. Serum samples were collected after informed signed consent and approval by the local Ethics Committee. In cohort 1, serum from CD (n=10) and UC (n=10) patients was obtained from commercial vendor Reprocell / Valley Biomedical in table 1. Serum from healthy subjects (HS) was also obtained from vendor Reprocell / Valley Biomedical (table 1). Serum samples from CD patients (n=44) in cohort 2 were obtained from Pavia, Italy, and serum samples from UC patients (n=29) (cohort 3) were obtained from Zagreb, Croatia, and additional 29 healthy donors were purchased from vendor Reprocell / Valley Biomedical (table 2). For CD patients, disease activity was assessed by Crohn’s disease Activity Index (CDAI). Patients with scores below 150 were classified as being in remission. In UC patients, disease activity was assessed according to the partial Mayo score for UC (pMayo). Clinical remission was defined as a score below 2.

**Statistics**

Statistical analysis was performed using MedCalc version 14 and GraphPad Prism version 7. The biomarker levels were presented as mean values and standard error of the mean (SEM). Key data was represented as Tukey plots with interquartile range (IQR). Mixed-effects analysis with Sidak’s test for multiple comparisons was applied for testing the differences in changes of PRO-C23 levels between DSS rats and controls and for testing differences in the DAI between DSS rats and controls.
Pearson $r$ correlation was applied for testing the association between serum PRO-C23 and DAI in DSS rats and controls. In human cohorts, age and gender were compared using a Kruskal-Wallis test. The differences of PRO-C23 between patients and healthy controls were determined by Kruskal-Wallis one-way ANOVA test, Dunn’s multiple comparisons test. The diagnostic power of biomarkers was investigated by the area under the receiver-operating characteristics (ROC) curve (AUC) with 95% confidence interval (CI). Sensitivity and specificity were determined for appropriate cut-off values based on the ROC curves. The significance threshold was set at $p<0.05$. 
Results

Characterization of PRO-C23 assay

Like type 23 collagen, type XIII and XXV collagens are also transmembrane collagens and share highly similar sequences in their C-terminus (Fig 2A). Western blot of recombinant type 23 collagen ectodomain (4165-CL, R&D system) showed that the chosen antibody 10F6 recognized type 23 collagen ectodomain around 60kD, while the reference commercial antibody (MAB4165, R&D system) was also shown (Fig 2B). 10F6 specifically recognized the last 10 amino acids of the C-terminus of type 23 collagen $^{531}$GLPVPGCWHK$^{540}$, but did not recognize the truncated peptide GLPVPGCWH, type XIII collagen C-terminal peptide GLPVQGCWNK, or type XXV collagen C-terminal peptide GLPMPGCWQK. It only weakly recognized elongated peptide GLPVPGCWHKA (Fig 2C).

PRO-C23 competitive ELISA provided a measurement range from 0.38 ng/ml (LLOD) to 18.73 ng/ml (ULOD). The inter- and intra-assay variabilities were 8.1% and 3.5%, respectively. The dilution recovery and spiking recovery in human serum were shown in Supplementary table 1. There was a significant correlation between human serum PRO-C23 values and EDTA values, heparin and citrate plasma values (EDTA; r=0.95, heparin; r=0.93, citrate; r=0.94, p<0.0001, Fig 2D), showing that PRO-C23 levels were independent of the blood preparation method.

PRO-C23 biomarker in DSS rat model

A rat model of DSS-induced colitis was used to investigate the biological relevance of the PRO-C23 assay. Compared to control rats, DSS rats had significantly higher DAI scores from day 2-11 in the acute DSS model (Fig 3A) and from day 5-56 in the chronic DSS model (Fig 3D), indicating colitis was successfully induced. The percentage change in serum PRO-C23 relative to baseline was significantly increased in DSS rats compared to controls at day 7 (p=0.027, Fig 3B), which returned to normal at day 16. Serum PRO-C23 and DAI was positively correlated at day 6 and 7 (Pearson r=0.50, p=0.04, Fig 3C). PRO-C23 was also modulated in the chronic DSS-induced colitis model, which demonstrated...
to be significantly different from baseline at blood sampling every day ($p<0.001$), except at day 56.

This statistical difference from baseline, however, was only seen in the DSS group and not in the control group (Fig 3E). Furthermore, serum PRO-C23 and DAI was positively correlated only at day 21 (Pearson $r=0.33$, $p=0.02$, Fig 3F) and 56 (Pearson $r=0.45$, $p=0.04$, Fig 3G).

Patient demographics

There were no statistical differences between the patient demographics (gender and age) of healthy donors, CD and UC patients in all cohorts (Table 1, Table 2).

PRO-C23 biomarker in human IBD cohorts

PRO-C23 was measured in serum from 3 independent human cohorts. In cohort 1, PRO-C23 was quantified in 10 CD (IQR: 2.074 ng/mL) and 10 UC (IQR: 1.09 ng/mL) patients, together with 10 age-matched healthy donors (IQR: 1.191 ng/mL). Results showed that CD (AUC=0.80; $p=0.02$) and UC (AUC: 0.80; $p=0.023$) patients have significantly higher levels of PRO-C23 compared to healthy donors (Fig 4).

PRO-C23 levels, in cohorts 2 and 3, were elevated in active CD patients (IQR: 2.288 ng/mL) and active UC patients (IQR: 2.87 ng/mL) compared to healthy donors (IQR: 1.02 ng/mL) (CD: AUC=0.70, $p<0.05$; UC: AUC=0.81 $p<0.01$; Fig 5). PRO-C23 serum levels were significantly elevated in patients with active disease compared to inactive disease for CD and UC. (CD: AUC=0.68, $p=0.05$; UC: AUC=0.75, $p<0.05$; Fig 5).
Discussion

IBD patients with active disease have increased intestinal permeability and mucosal damage, including loss of epithelial integrity[24]. The tight junction/adhesion proteins, such as E-cadherin and β-catenin, are dramatically down-regulated in inflamed tissue of IBD patients [7]. Therefore, proteins related to the intestinal epithelium for assessing intestinal permeability/epithelial integrity and intestinal tissue homeostasis may be used to evaluate the disease burden [1,11,13–15,25–27].

The antibody in the PRO-C23 ELISA only recognized the C-terminus sequence of type 23 collagen and had no cross-reaction with the C-terminus of type XIII and XXV collagen, which have similar sequences. This data confirmed the specificity of the antibody. Our data demonstrated that the ectodomain of type 23 collagen could be detected in the circulation by the PRO-C23 competitive ELISA in serum and plasma samples.

We found that type 23 collagen was significantly elevated in DSS rats, and it weakly correlated with disease activity in both the acute (day 6 and 7, Fig. 3) and chronic DSS colitis model (day 21 and 56, Fig 3). This finding indicated that the ectodomain of type 23 collagen found in circulation related to disease activity of DSS rats, and these data were in agreement with the study by Lindholm et al. which demonstrated that markers of type III collagen remodeling (interstitial matrix) and markers of type IV collagen remodeling (basement membrane) were also elevated in the DSS model [14].

Furthermore, the continuous elevated levels of PRO-C23 in the chronic DSS colitis model indicate the remodeling of type 23 collagen is ongoing during induction of inflammation and in the healing phases. This can be explained by the involvement of type 23 collagen in cell migration, which is necessary for epithelial restitution.

To further validate the PRO-C23 biomarker, it was measured in 2 additional human cohorts. PRO-C23 was found elevated in human CD patients (cohort 2) and UC patients (cohort 3) with active disease, and it was also able to differentiate between UC and CD vs. healthy subjects and active disease vs. inactive disease for both UC and CD. These data suggested that the release of the
ectodomain of type 23 collagen was reinforced in the active intestinal damage, which was consistent with the animal model results.

It is believed that type 23 collagen facilitates cell-cell adhesion and cell-matrix adhesion [22]. Silencing type 23 collagen in lung cancer and clear cell renal cell lines showed altered adhesion protein expressions and less ability on cell adhesion and migration [22,23]. However, type 23 collagen is also present in other tissues, and the function and use in other diseases are yet unknown.

To our knowledge, this is the first study showing that type 23 collagen level is modulated in IBD. Our results indicate that PRO-C23 is not specific for either UC or CD, but more related to the process of intestinal mucosal remodelling, affecting the epithelium equally in UC and CD (Figures 4 and 5). Furthermore, since PRO-C23 measures the shedding of type 23 collagen from epithelial cells, this assay may be used as a monitoring tool to evaluate the integrity of the intestinal mucosal epithelium. Whether increased levels of PRO-C23 is solely a consequence of inflammation or also an contributor to the pathogenesis in IBD patients is unknown. If type 23 collagen is essential for restitution of intestinal epithelial cells, it is possible the underlying dysregulation of the collagen may adversely affect healing of the inflamed intestine.

There are several limitations to this study. Firstly, we cannot exclude that PRO-C23 may be released from other tissues than the intestines; however, the DSS colitis models confirm that PRO-C23 is a product of the intestinal mucosa remodeling suggesting that PRO-C23 at least is derived from the intestines. Secondly, the number of patients in this study is low. The fact that the IBD patients were recruited at different medical institutes may introduce discrepancies e.g., in sample handling and disease activity scoring. The PRO-C23 assay, however, was still able to obtain similar results in the IBD cohorts included. While PRO-C23 only showed a weak correlation to DAI in the DSS models, PRO-C23 was demonstrated to be elevated in IBD patients with active disease. Therefore, more clinical studies in comprehensive cohorts are needed to evaluate this biomarker further.
Conclusion

This is the first study showing elevated serum levels of type 23 collagen in IBD, and consequently, that transmembrane collagens and the basement membrane axis is essential for the pathology of IBD. PRO-C23 was found elevated in both the acute and chronic rat DSS colitis model and patients with active CD and UC. This indicates that PRO-C23 is associated with a compromised interstitial mucosa and epithelial cell dysfunction. PRO-C23 may potentially be used as a non-invasive surrogate of disease activity in CD and UC patients and thus aid in the diagnosis and monitoring of patients.

V. Domislović, P. Giuffrida, M. Brinar, G. Mazza, M Pinzani, Ž. Krznarić, A. Di Sabatino has no conflict of interests

Ethics approval

Production of monoclonal antibodies performed in mice was approved by the National Authority (The Animal Experiments Inspectorate) under approval number 2013-15-2934-00956. All animals were treated according to the guidelines for animal welfare.

Informed consent

Informed consent and approval by the local Ethics Committee were obtained before sample collection and the studies were performed in compliance with the Helsinki Declaration of 1975.
References

[1] S.C. Bischoff, G. Barbara, W. Buurman, T. Ockhuizen, J.D. Schulzke, M. Serino, H. Tilg, A. Watson, J.M. Wells, Intestinal permeability - a new target for disease prevention and therapy, BMC Gastroenterol. 14 (2014). doi:10.1186/s12876-014-0189-7.

[2] K.R. Groschwitz, S.P. Hogan, Intestinal barrier function: molecular regulation and disease pathogenesis., J. Allergy Clin. Immunol. 124 (2009) 3–20; quiz 21–2. doi:10.1016/j.jaci.2009.05.038.

[3] P. Giuffrida, G.R. Corazza, A. Di Sabatino, Old and New Lymphocyte Players in Inflammatory Bowel Disease, Dig. Dis. Sci. 63 (2018) 277–288. doi:10.1007/s10620-017-4892-4.

[4] J. Chang, R.W. Leong, V.C. Wasinger, M. Ip, M. Yang, T.G. Phan, Impaired Intestinal Permeability Contributes to Ongoing Bowel Symptoms in Patients With Inflammatory Bowel Disease and Mucosal Healing, Gastroenterology. 153 (2017) 723-731.e1. doi:10.1053/j.gastro.2017.05.056.

[5] J. Banyard, L. Bao, B.R. Zetter, Type XXIII collagen, a new transmembrane collagen identified in metastatic tumor cells, J. Biol. Chem. 278 (2003) 20989–20994. doi:10.1074/jbc.M210616200.

[6] G. Veit, E.P. Zimina, C.W. Franzke, S. Kutsch, U. Siebolds, M.K. Gordon, L. Bruckner-Tuderman, M. Koch, Shedding of collagen XXIII is mediated by furin and depends on the plasma membrane microenvironment, J. Biol. Chem. 282 (2007) 27424–27435. doi:10.1074/jbc.M703425200.

[7] N. Gassler, C. Rohr, a Schneider, J. Kartenbeck, a Bach, N. Obermüller, H.F. Otto, F. Autschbach, Inflammatory bowel disease is associated with changes of enterocytic junctions., Am. J. Physiol. Gastrointest. Liver Physiol. 281 (2001) G216–G228. doi:10.1152/ajpgi.2001.281.1.G216.

[8] H. Ohta, Y. Sunden, N. Yokoyama, T. Osuga, S.Y. Lim, Y. Tamura, K. Morishita, K. Nakamura,
M. Yamasaki, M. Takiguchi, Expression of apical junction complex proteins in duodenal mucosa of dogs with inflammatory bowel disease, Am. J. Vet. Res. 75 (2014) 746–751. doi:10.2460/ajvr.75.8.746.

[9] A.J. Karayiannakis, K.N. Syrigos, J. Efstathiou, A. Valizadeh, M. Noda, R.J. Playford, W. Kmiot, M. Pignatelli, Expression of catenins and E-cadherin during epithelial restitution in inflammatory bowel disease, J. Pathol. 185 (1998) 413–418. doi:10.1002/(SICI)1096-9896(199808)185:4<413::AID-PATH125>3.0.CO;2-K.

[10] A. Dogan, Z.D. Wang, J. Spencer, E-cadherin expression in intestinal epithelium, J Clin Pathol. 48 (1995) 143–146. doi:10.1136/jcp.48.2.143.

[11] J.H. Mortensen, L.E. Godskesen, M.D. Jensen, W.T. Van Haaften, L.G. Klinge, P. Olinga, G. Dijkstra, J. Kjeldsen, M.A. Karsdal, A.C. Bay-Jensen, A. Krag, Fragments of Citrullinated and MMP-degraded Vimentin and MMP-degraded Type III Collagen Are Novel Serological Biomarkers to Differentiate Crohn’s Disease from Ulcerative Colitis, J. Crohn’s Colitis. (2015) jjv123. doi:10.1093/ecco-jcc/jjv123.

[12] W.T. van Haaften, J.H. Mortensen, M.A. Karsdal, A.C. Bay-Jensen, G. Dijkstra, P. Olinga, Misbalance in type III collagen formation/degradation as a novel serological biomarker for penetrating (Montreal B3) Crohn’s disease, Aliment. Pharmacol. Ther. (2017). doi:10.1111/apt.14092.

[13] J.H. Mortensen, T. Manon-Jensen, M.D. Jensen, P. Hägglund, L.G. Klinge, J. Kjeldsen, A. Krag, M.A. Karsdal, A.C. Bay-Jensen, Ulcerative colitis, Crohn’s disease, and irritable bowel syndrome have different profiles of extracellular matrix turnover, which also reflects disease activity in Crohn’s disease, PLoS One. 12 (2017) 1–16. doi:10.1371/journal.pone.0185855.

[14] M. Lindholm, T. Manon-Jensen, G.I. Madsen, A. Krag, M.A. Karsdal, J. Kjeldsen, J.H. Mortensen, Extracellular Matrix Fragments of the Basement Membrane and the Interstitial
Matrix Are Serological Markers of Intestinal Tissue Remodeling and Disease Activity in Dextran Sulfate Sodium Colitis, Dig. Dis. Sci. (2019). doi:10.1007/s10620-019-05676-6.

[15] J.H. Mortensen, M. Lindholm, L.L. Langholm, J. Kjeldsen, A.-C. Bay-Jensen, M.A. Karsdal, T. Manon-Jensen, The intestinal tissue homeostasis – the role of extracellular matrix remodeling in inflammatory bowel disease, Expert Rev. Gastroenterol. Hepatol. 00 (2019) 1–17. doi:10.1080/17474124.2019.1673729.

[16] E. Shimshoni, D. Yablecovitch, L. Baram, I. Dotan, I. Sagi, ECM remodelling in IBD: innocent bystander or partner in crime? The emerging role of extracellular molecular events in sustaining intestinal inflammation, Gut. 64 (2015) 367–372. doi:10.1136/gutjnl-2014-308048.

[17] A. Ravi, P. Garg, S. V Sitaraman, Matrix metalloproteinases in inflammatory bowel disease: boon or a bane?, Inflamm. Bowel Dis. 13 (2007) 97–107. doi:10.1002/ibd.20011.

[18] A.C. Petrey, C.A. De La Motte, The extracellular matrix in IBD: A dynamic mediator of inflammation, Curr. Opin. Gastroenterol. 33 (2017) 234–238. doi:10.1097/MOG.0000000000000368.

[19] P. Giuffrida, P. Biancheri, T.T. Macdonald, Proteases and small intestinal barrier function in health and disease, Curr Opin Gastroenterol. 30 (2014) 147–153. doi:10.1097/MOG.0000000000000042.

[20] C. Jensen, S.H. Nielsen, J.H. Mortensen, J. Kjeldsen, L.G. Klinge, A. Krag, H. Harling, L.N. Jørgensen, M.A. Karsdal, N. Willumsen, Serum type XVI collagen is associated with colorectal cancer and ulcerative colitis indicating a pathological role in gastrointestinal disorders, Cancer Med. 7 (2018) 4619–4626. doi:10.1002/cam4.1692.

[21] S. Holm Nielsen, J.H. Mortensen, N. Willumsen, D.G.K. Rasmussen, D.J. Mogensen, A. Di Sabatino, G. Mazza, L.N. Jørgensen, P. Giuffrida, M. Pinzani, L. Klinge, J. Kjeldsen, D.J. Leeming, M.A. Karsdal, F. Genovese, A Fragment of Collagen Type VI alpha-3 chain is
Elevated in Serum from Patients with Gastrointestinal Disorders, Sci. Rep. 10 (2020) 1–9. doi:10.1038/s41598-020-62474-1.

[22] K.A. Spivey, I. Chung, J. Banyard, I. Adini, H.A. Feldman, B.R. Zetter, A role for collagen XXIII in cancer cell adhesion, anchorage-independence and metastasis, Oncogene. 31 (2012) 2362–2372. doi:10.1038/onc.2011.406.

[23] F. Xu, K. Chang, J. Ma, Y. Qu, H. Xie, B. Dai, H. Gan, H. Zhang, G. Shi, Y. Zhu, Y. Zhu, Y. Shen, D. Ye, The Oncogenic Role of COL23A1 in Clear Cell Renal Cell Carcinoma, Sci. Rep. 7 (2017) 9846. doi:10.1038/s41598-017-10134-2.

[24] R. D’Incà, V. Di Leo, G. Corrao, D. Martines, A. D’Odorico, C. Mestriner, C. Venturi, G. Longo, G.C. Sturniolo, Intestinal permeability test as a predictor of clinical course in Crohn’s disease., Am. J. Gastroenterol. 94 (1999) 2956–60. doi:10.1111/j.1572-0241.1999.01444.x.

[25] W.T. Van Haaften, J.H. Mortensen, M.A. Karsdal, A.C. Bay-Jensen, G. Dijkstra, P. Olinga, Misbalance in type III collagen formation/degradation as a novel serological biomarker for penetrating (Montreal B3) Crohn’s disease, Aliment. Pharmacol. Ther. (2017) 26–39. doi:10.1111/apt.14092.

[26] J.H. Mortensen, W.T. van Haaften, M.A. Karsdal, A.-C. Bay-Jensen, P. Olinga, H. Grønbæk, C.L. Hvas, T. Manon-Jensen, G. Dijkstra, A. Dige, The Citrullinated and MMP-degraded Vimentin Biomarker (VICM) Predicts Early Response to Anti-TNFα Treatment in Crohn’s Disease, J. Clin. Gastroenterol. Publish ab (2020). doi:10.1097/MCG.0000000000001341.

[27] G. D’Haens, M. Ferrante, S. Vermeire, F. Baert, M. Noman, L. Moortgat, P. Geens, D. Iwens, I. Aerden, G. Van Assche, G. Van Olmen, P. Rutgeerts, Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease, Inflamm. Bowel Dis. 18 (2012) 2218–2224. doi:10.1002/ibd.22917.

[28] M.A. Karsdal, D.J. Leeming, K. Heniksen, A.-C. Bay-Jensen, S.H. Nielsen, C.L. Bager, Biochemistry of Collagens, Laminins and Elastin: Structure, Function and Biomarkers, 2nd
**Figure Legend**

**Figure 1:** The tertiary structure of type XXIII collagen and furin mediated shedding of type XXIII collagen. Type XXIII is a transmembrane collagen expressed by epithelial cells but also exists as a soluble protein after furin mediated shedding. Type XXIII collagen consists of a transmembrane domain, 3 collagenous domains (triple helical domains), and 3 non-collagenous domains. The soluble form of type XXIII may also form multimeric complexes. Adapted from *Karsdal et al. 2019* [28].

**Figure 2:** Specificity assessment of the PRO-C23 antibody 10F6. A) Sequence alignment for C-terminus of type XIII, XXIII, and XXV collagens. The antibody recognizes the residues from 531 to 540 of type 23 collagen. B) Western blot results of recombinant type 23 collagen using 10F6 as a primary antibody. C) PRO-C23 antibody specificity towards different peptides. Reactivity to the type XXIII collagen selection peptide (GLPVPGCWHK), the elongated peptide (GLPVPGCWHA), the truncated peptide (GLPVPGCW), a peptide from type XIII collagen (GLPVQGCWKN) and peptide from type XXV collagen (GLPMPGCWQK) was tested in the PRO-C23 assay. D) Correlations of PRO-C23 levels serum levels with the levels of the EDTA, heparin and citrate plasma (n=16).

**Figure 3:** PRO-C23 serum levels during models of acute DSS colitis (figure A-C) and chronic DSS colitis (figure D-G). A) DAI for DSS rats and controls during and after DSS administration in the acute DSS model; B) Percentage PRO-C23 serum levels relative to baseline in DSS rats and controls in the acute DSS model; C) Correlation between PRO-C23 serum levels and DAI at day 6 and 7; D) DAI for DSS rats and controls during and after DSS administration in the chronic DSS model; E) Percentage change of PRO-C23 serum levels relative to baseline in DSS rats and controls in the chronic DSS model; F) Correlation between PRO-C23 serum levels and DAI at day 21 and G) day 56.
Asterisks (*) represent statistical differences, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 from baseline.

Figure 4: PRO-C23 serum levels in cohort 1 for healthy subjects (HS), UC and CD (figure A), and its discriminative power to differentiate between HS and CD/UC (figure B-C). * represents p<0.05.

Figure 5: PRO-C23 serum levels in cohort 2 (CD), cohort 3 (UC) and healthy subjects (HS) (figure A-B), and its discriminative power to differentiate between HS and CD and UC patients (figure C-D) and between active disease vs. inactive disease in CD and UC patients (figure E-F). Asterisks (*) represent statistical differences, (*) p<0.10, *p<0.05, ***p<0.001.